Vaccine-associated inflammatory diseases of the central nervous system: From signals to causation

Current Opinion in Neurology

Volumn 29, Issue 3, 2016, Pages 362-371

  Nguyen, Xuan Hung ^a,b,c   Saoudi, Abdelhadi ^a,b,c   Liblau, Roland S ^a,b,c  

^a CHU PURPAN   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

autoimmunity; central nervous system; multiple sclerosis; narcolepsy; vaccination

Indexed keywords

BCG VACCINE; CHOLERA VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA POLIOMYELITIS TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; RUBELLA VACCINE; SMALLPOX VACCINE; TETANUS TOXOID; TYPHOID VACCINE; VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; CATAPLEXY; DRUG SAFETY; EPIDEMIOLOGICAL DATA; GUILLAIN BARRE SYNDROME; HUMAN; INFLUENZA A VIRUS (H1N1); INFLUENZA VACCINATION; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NARCOLEPSY; NERVOUS SYSTEM INFLAMMATION; REVIEW; VACCINATION; AUTOIMMUNITY; CHEMICALLY INDUCED; INFLAMMATION; NEUROLOGIC DISEASE; PROSPECTIVE STUDY;

AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; AUTOIMMUNITY; HUMANS; INFLAMMATION; PROSPECTIVE STUDIES; VACCINATION; VACCINES;

EID: 84961907097     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000318     Document Type: Review

References (165)

1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801.
2. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811.
3. Pasquale AD, Preiss S, Silva FT, et al. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines (Basel) 2015; 3:320-343.
4. Pellegrino P, Clementi E, Radice S. On vaccine's adjuvants and autoimmu-nity: current evidence and future perspectives. Autoimmun Rev 2015; 14:880-888.
5. Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet 2003; 362:1659-1666.
6. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347:911-920.
7. Horwitz MS, Bradley LM, Harbertson J, et al. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med 1998; 4:781-785.
8. Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 2001; 108:1097-1104.
9. Rees JH, Gregson NA, Hughes RA. Antiganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995; 38:809-816.
10. Fujinami RS, Oldstone MB. Amino acid homology between the encephalito-genic site of myelin basic protein and virus: mechanism for autoimmunity. Science 1985; 230:1043-1045.
11. Olson JK, Croxford JL, Calenoff MA, et al. A virus-induced molecular mimicry model of multiple sclerosis. J Clin Invest 2001; 108:311-318.
12. Panoutsakopoulou V, Sanchirico ME, Huster KM, et al. Analysis of the relationship between viral infection and autoimmune disease. Immunity 2001; 15:137-147.
13. Miller SD, Olson JK, Croxford JL. Multiple pathways to induction of virus-induced autoimmune demyelination: lessons from Theiler's virus infection. J Autoimmun 2001; 16:219-227.
14. Kissler S, Anderton SM, Wraith DC. Antigen-presenting cell activation: a link between infection and autoimmunity? J Autoimmun 2001; 16:303-308.
15. Guimaraes LE, Baker B, Perricone C, et al. Vaccines, adjuvants and auto-immunity. Pharmacol Res 2015; 100:190-209.
16. Karussis D, Petrou P. The spectrum of postvaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev 2014; 13:215-224.
17. Vrethem M, Malmgren K, Lindh J. A patient with both narcolepsy and multiple sclerosis in association with Pandemrix vaccination. J Neurol Sci 2012; 321:89-91.
18. Rabello GD. Postvaccinal neurological complications. Arq Neuropsiquiatr 2013; 71:747-751.
19. Sutton I, Lahoria R, Tan I, et al. CNS demyelination and quadrivalent HPV vaccination. Mult Scler 2009; 15:116-119.
20. Miller H, Cendrowski W, Shapira K. Multiple sclerosis and vaccination. Br Med J 1967; 2:210-213.
21. Herroelen L, de Keyser J, Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet 1991; 338:1174-1175.
22. Hernan MA, Jick SS, Olek MJ, et al. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2004; 63:838-842.
23. Tourbah A, Gout O, Liblau R, et al. Encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS? Neurology 1999; 53:396-401.
24. Gout O, Lyon-Caen O. Sclerotic plaques and vaccination against hepatitis B. Rev Neurol (Paris) 1998; 154:205-207.
25. Mikaeloff Y, Caridade G, Suissa S, et al. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology 2009; 72:873-880.
26. Kumar R, Singh AK, Pradhan RN, et al. A case report of post Rabipur (purified chick embryo rabies vaccine) acute disseminated encephalomyelitis. J Assoc Physicians India 2015; 63:56-58.
27. Santhoshkumar A, Kalpana D, Sowrabha R. Rabies encephalomyelitis vs. ADEM: usefulness of MR imaging in differential diagnosis. J Pediatr Neurosci 2012; 7:133-135.
28. Murthy JM. MRI in acute disseminated encephalomyelitis following Semple antirabies vaccine. Neuroradiology 1998; 40:420-423.
29. Gamboa ET, Cowen D, Eggers A, et al. Delayed onset of postrabies vaccination encephalitis. Ann Neurol 1983; 13:676-678.
30. Iizuka H, Amano N, Izeki E, et al. A case of antirabies inoculation encephalitis with a long clinical course. Jpn J Psychiatry Neurol 1993; 47:603-608.
31. Kulkarni V, Nadgir D, Tapiawala S, et al. Biphasic demyelination of the nervous system following antirabies vaccination. Neurol India 2004; 52:106-108.
32. Pellegrino P, Radice S, Clementi E. Acute disseminated encephalomyelitis following influenza vaccine. Epidemiology 2015; 26:e12-e13.
33. Alicino C, Infante MT, Gandoglia I, et al. Acute disseminated encephalo-myelitis with severe neurological outcomes following virosomal seasonal influenza vaccine. Hum Vaccin Immunother 2014; 10:1969-1973.
34. Machicado JD, Bhagya-Rao B, Davogustto G, et al. Acute disseminated encephalomyelitis following seasonal influenza vaccination in an elderly patient. Clin Vaccine Immunol 2013; 20:1485-1486.
35. Fujii K, Suyama M, Chiba K, et al. Acute disseminated encephalomyelitis following 2009 H1N1 influenza vaccine. Pediatr Int 2012; 54:539-541.
36. Becker MM, Ranzan J, Magalhaes LV, et al. Post-H1N1 vaccine acute disseminated encephalomyelitis. Pediatr Int 2014; 56:437-438.
37. Maeda K, Idehara R. Acute disseminated encephalomyelitis following 2009 H1N1 influenza vaccination. Intern Med 2012; 51:1931-1933.
38. Hoshino T, Uchiyama Y, Ito E, et al. Simultaneous development of acute disseminated encephalomyelitis and Guillain-Barré syndrome associated with H1N1 09 influenza vaccination. Intern Med 2012; 51:1595-1598.
39. Lee ST, Choe YJ, Moon WJ, et al. An adverse event following 2009 H1N1 influenza vaccination: a case of acute disseminated encephalomyelitis. Korean J Pediatr 2011; 54:422-424.
40. Fernandes AF, Marchiori PE. Bithalamic compromise in acute disseminated encephalomyelitis following H1N1 influenza vaccine. Arq Neuropsiquiatr 2011; 69:571.
41. Shoamanesh A, Traboulsee A. Acute disseminated encephalomyelitis following influenza vaccination. Vaccine 2011; 29:8182-8185.
42. Denholm JT, Neal A, Yan B, et al. Acute encephalomyelitis syndromes associated with H1N1 09 influenza vaccination. Neurology 2010; 75:2246-2248.
43. Ravaglia S, Ceroni M, Moglia A, et al. Postinfectious and postvaccinal acute disseminated encephalomyelitis occurring in the same patients. J Neurol 2004; 251:1147-1150.
44. Saito H, Endo M, Takase S, et al. Acute disseminated encephalomyelitis after influenza vaccination. Arch Neurol 1980; 37:564-566.
45. Turkoglu R, Tuzun E. Brainstem encephalitis following influenza vaccination: favorable response to steroid treatment. Vaccine 2009; 27:7253-7256.
46. Kavadas FD, Bitnun A, MacGregor D, et al. Acute neurological events associated with influenza vaccination: are the WHO criteria for assessing causality adequate? Scand J Infect Dis 2008; 40:565-570.
47. Huynh W, Cordato DJ, Kehdi E, et al. Postvaccination encephalomyelitis: literature review and illustrative case. J Clin Neurosci 2008; 15:1315-1322.
48. Nakamura N, Nokura K, Zettsu T, et al. Neurologic complications associated with influenza vaccination: two adult cases. Intern Med 2003; 42:191-194.
49. Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 2005; 294:2720-2725.
50. Iyoda K, Mitsuda N, Ogawa K, et al. The head MRI by fluid attenuated inversion recovery (FLAIR) was useful for diagnosis in the patient with post influenza vaccinal acute disseminated encephalomyelitis (ADEM). No To Hattatsu 2004; 36:401-406.
51. Vilain S, Waterschoot MP, Mavroudakis N. Encephalomyelitis and bilateral optic perineuritis after influenza vaccination. Bull Soc Belge Ophtalmol 2000; 277:71-73.
52. Wildemann B, Jarius S, Hartmann M, et al. Acute disseminated encephalo-myelitis following vaccination against human papilloma virus. Neurology 2009; 72:2132-2133.
53. Schaffer V, Wimmer S, Rotaru I, et al. HPV vaccine: a cornerstone of female health a possible cause of ADEM? J Neurol 2008; 255:1818-1820.
54. Mendoza Plasencia Z, Gonzalez Lopez M, Fernandez Sanfiel ML, et al. Acute disseminated encephalomyelitis with tumefactive lesions after vaccination against human papillomavirus. Neurologia 2010; 25:58-59.
55. Pellegrino P, Carnovale C, Perrone V, et al. Can HPV immunisation cause ADEM? Twocasereports andliteraturereview. Mult Scler 2014;20:762-763.
56. DiMario FJ Jr, Hajjar M, Ciesielski T. A 16-year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus. J Child Neurol 2010; 25:321-327.
57. Miravalle A, Biller J, Silva E, et al. Acute disseminated encephalomyelitis: yellow fever vaccination. Arq Neuropsiquiatr 2009; 67:710-711.
58. Cabrera-Gomez JA, Echazabal-Santana N, Garcia Gonzalez L, et al. A severe episode in a patient with recurrent disseminated acute encephalitis due to vaccination against hepatitis B. For or against vaccination? Rev Neurol 2002; 34:358-363.
59. Konstantinou D, Paschalis C, Maraziotis T, et al. Two episodes of leukoen-cephalitis associated with recombinant hepatitis B vaccination in a single patient. Clin Infect Dis 2001; 33:1772-1773.
60. Huber S, Kappos L, Fuhr P, et al. Combined acute disseminated encepha-lomyelitis and acute motor axonal neuropathy after vaccination for hepatitis A and infection with Campylobacter jejuni. J Neurol 1999; 246:1204-1206.
61. Shibazaki K, Murakami T, Kushida R, et al. Acute disseminated encephalo-myelitis associated with oral polio vaccine. Intern Med 2006; 45:1143-1146.
62. Ozawa H, Noma S, Yoshida Y, et al. Acute disseminated encephalomyelitis associated with poliomyelitis vaccine. Pediatr Neurol 2000; 23:177-179.
63. Tsuru T, Mizuguchi M, Ohkubo Y, et al. Acute disseminated encephalomye-litis after live rubella vaccination. Brain Dev 2000; 22:259-261.
64. Bolukbasi O, Ozmenoglu M. Acute disseminated encephalomyelitis associated with tetanus vaccination. Eur Neurol 1999; 41:231-232.
65. Hamidon BB, Raymond AA. Acute disseminated encephalomyelitis (ADEM) presenting with seizures secondary to antitetanus toxin vaccination. Med J Malaysia 2003; 58:780-782.
66. Cisse FA, Sidibe H, Morel Y, et al. Acute disseminated encephalomyelitis after tetanus vaccination of a pregnant woman in Senegal. Med Sante Trop 2012; 22:103-105.
67. Shu M, Liu Q, Wang J, et al. Measles vaccine adverse events reported in the mass vaccination campaign of Sichuan province, China from 2007 to 2008. Vaccine 2011; 29:3507-3510.
68. Aydin H, Ozgul E, Agildere AM. Acute necrotizing encephalopathy secondary to diphtheria, tetanus toxoid and whole-cell pertussis vaccination: diffusion-weighted imaging and proton MR spectroscopy findings. Pediatr Radiol 2010; 40:1281-1284.
69. Mancini J, Chabrol B, Moulene E, et al. Relapsing acute encephalopathy: a complication of diphtheria-tetanus-poliomyelitis immunization in a young boy. Eur J Pediatr 1996; 155:136-138.
70. Sejvar JJ, Labutta RJ, Chapman LE, et al. Neurologic adverse events associated with smallpox vaccination in the United States. JAMA 2005; 294:2744-2750.
71. Dauvilliers Y, Montplaisir J, Cochen V, et al. Post-H1N1 narcolepsy-cata-plexy. Sleep 2010; 33:1428-1430.
72. Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 2012; 7:e33723.
73. Wijnans L, Lecomte C, de Vries C, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013; 31:1246-1254.
74. Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012; 7:e33536.
75. Sweden Medical Products Agency. Occurrence of narcolepsy with cataplexy among children and adolescents in relation to the H1N1 pandemic and Pandemrix vaccinations-results of a case inventory study by the MPA in Sweden during 2009-2010. 2011.
76. O'Flanagan D, Barret AS, Foley M, et al. Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine, Ireland April 2009-December 2010. Euro Surveill 2014; 19:15-25.
77. Miller E, Andrews N, Stellitano L, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013; 346:f794.
78. Heier MS, Gautvik KM, Wannag E, et al. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med 2013; 14:867-871.
79. Dauvilliers Y, Arnulf I, Lecendreux M, et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain 2013; 136:2486-2496.
80. Oberle D, Drechsel-Bauerle U, Schmidtmann I, et al. Incidence of narcolepsy in Germany. Sleep 2015; 38:1619-1628.
81. Persson I, Granath F, Askling J, et al. Risks of neurological and immunerelated diseases, including narcolepsy, after vaccination with Pandemrix: a population-and registry-based cohort study with over 2 years of follow-up. J Intern Med 2014; 275:172-190.
82. Austin A, Tincani A, Kivity S, et al. Transverse myelitis activation post-H1N1 immunization: a case of adjuvant induction? Isr Med Assoc J 2015; 17:120-122.
83. Vieira MA, Costa CH, Vieira CP, et al. Transverse myelitis with Brown-Sequard syndrome after H1N1 immunization. Arq Neuropsiquiatr 2012; 70:555.
84. Ambrose CS, Loop B, Miday R. A case report of transverse myelitis following influenza vaccination. Arch Neurol 2011; 68:1085-1086.
85. Korn-Lubetzki I, Dano M, Raveh D. H1N1 vaccine-related acute transverse myelitis. Isr Med Assoc J 2011; 13:249-250.
86. Gui L, Chen K, Zhang Y. Acute transverse myelitis following vaccination against H1N1 influenza: a case report. Int J Clin Exp Pathol 2011; 4:312-314.
87. Sato N, Watanabe K, Ohta K, et al. Acute transverse myelitis and acute motor axonal neuropathy developed after vaccinations against seasonal and 2009 A/H1N1 influenza. Intern Med 2011; 50:503-507.
88. Akkad W, Salem B, Freeman JW, et al. Longitudinally extensive transverse myelitis following vaccination with nasal attenuated novel influenza A(H1N1) vaccine. Arch Neurol 2010; 67:1018-1020.
89. Lessa R, Castillo M, Azevedo R, et al. Neurological complications after H1N1 influenza vaccination: magnetic resonance imaging findings. Arq Neuropsi-quiatr 2014; 72:496-499.
90. Arcondo MF, Wachs A, Zylberman M. Transverse myelitis associated with antiinfluenza A (H1N1) vaccination. Medicina (B Aires) 2011; 71:161-164.
91. Kozic D, Turkulov V, Bjelan M, et al. Extensive myelitis after oral polio vaccination: MRI features. JBR-BTR 2014; 97:358-360.
92. Kelly H. Evidence for a causal association between oral polio vaccine and transverse myelitis: a case history and review of the literature. J Paediatr Child Health 2006; 42:155-159.
93. Bussell LJ. Myelitis after antirabic vaccine; report of a fatal case. Lancet 1946; 2:826.
94. Ansell I. A fatal case of myelitis after antirabic vaccine. Br Med J 1948; 2:338-340.
95. Prussin G, Katabi G. Dorsolumbar myelitis following antirabies vaccination with duck embryo vaccine. Ann Intern Med 1964; 60:114-116.
96. Label LS, Batts DH. Transverse myelitis caused by duck embryo rabies vaccine. Arch Neurol 1982; 39:426-430.
97. Bir LS, Esmeli FO, Cenikli U, et al. Acute transverse myelitis at the conus medullaris level after rabies vaccination in a patient with Behcet's disease. J Spinal Cord Med 2007; 30:294-296.
98. Joyce KA, Rees JE. Transverse myelitis after measles, mumps, and rubella vaccine. BMJ 1995; 311:422.
99. Karaali-Savrun F, Altintas A, Saip S, et al. Hepatitis B vaccine related-myelitis? Eur J Neurol 2001; 8:711-715.
100. Fonseca LF, Noce TR, Teixeira ML, et al. Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report. Arq Neuropsiquiatr 2003; 61:265-268.
101. Song HK, Kim HC, Yun YH. Acute myelitis after hepatitis B vaccination. J Korean Med Sci 1997; 12:249-251.
102. Trevisani F, Gattinara GC, Caraceni P, et al. Transverse myelitis following hepatitis B vaccination. J Hepatol 1993; 19:317-318.
103. Lim S, Park SM, Choi HS, et al. Transverse myelitis after measles and rubella vaccination. J Paediatr Child Health 2004; 40:583-584.
104. Kline LB, Margulies SL, Oh SJ. Optic neuritis and myelitis following rubella vaccination. Arch Neurol 1982; 39:443-444.
105. Holt S, Hudgins D, Krishnan KR, et al. Diffuse myelitis associated with rubella vaccination. Br Med J 1976; 2:1037-1038.
106. Read SJ, Schapel GJ, Pender MP. Acute transverse myelitis after tetanus toxoid vaccination. Lancet 1992; 339:1111-1112.
107. D'Costa DF, Cooper A, Pye IF. Transverse myelitis following cholera, typhoid and polio vaccination. J R Soc Med 1990; 83:653.
108. Hamano T, Takeda T, Morita H, et al. Posterior reversible encephalopathy syndrome following measles vaccination. J Neurol Sci 2010; 298:124-126.
109. Menge T, Cree B, Saleh A, et al. Neuromyelitis optica following human papillomavirus vaccination. Neurology 2012; 79:285-287.
110. Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 2002; 85:131-134.
111. Chaves M, Riccio P, Patrucco L, et al. Longitudinal myelitis associated with yellow fever vaccination. J Neurovirol 2009; 15:348-350.
112. Heekin R, Gandhy C, Robertson D. Seronegative neuromyelitis optica spectrum disorder following exposure to hepatitis B vaccination. Case Rep Neurol 2015; 7:78-83.
113. Annunziata P, Carnicelli N, Galluzzi P, et al. Miller-Fisher syndrome following vaccination against influenza virus A/H1N1 in an AIDS patient. Infection 2012; 40:97-99.
114. Shoamanesh A, Chapman K, Traboulsee A. Postvaccination Miller Fisher syndrome. Arch Neurol 2011; 68:1327-1329.
115. Blanco-Marchite CI, Buznego-Suarez L, Fagundez-Vargas MA, et al. Miller Fisher syndrome, internal and external ophthalmoplegia after flu vaccination. Arch Soc Esp Oftalmol 2008; 83:433-435.
116. Thaler A. Miller Fisher syndrome in a 66-year-old female after flu and pneumovax vaccinations. J Am Med Dir Assoc 2008; 9:283-284.
117. De Keyser J, Zwanikken C, Boon M. Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 1998; 159:51-53.
118. Zipp F, Weil JG, Einhaupl KM. No increase in demyelinating diseases after hepatitis B vaccination. Nat Med 1999; 5:964-965.
119. Sadovnick AD, Scheifele DW. School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet 2000; 355:549-550.
120. Ascherio A, Zhang SM, Hernan MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001; 344:327-332.
121. Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001; 344:319-326.
122. Piaggio E, Ben Younes A, Desbois S, et al. Hepatitis B vaccination and central nervous system demyelination: an immunological approach. J Auto-immun 2005; 24:33-37.
123. Chang J, Campagnolo D, Vollmer TL, et al. Demyelinating disease and polyvalent human papilloma virus vaccination. J Neurol Neurosurg Psychiatry 2011; 82:1296-1298.
124. Langer-Gould A, Qian L, Tartof SY, et al. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol 2014; 71:1506-1513.
125. Scheller NM, Svanstrom H, Pasternak B, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA 2015; 313:54-61.
126. Vichnin M, Bonanni P, Klein NP, et al. An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015. Pediatr Infect Dis J 2015; 34:983-991.
127. Mereckiene J, Cotter S, Weber JT, et al. Influenza A(H1N1)pdm09 vaccination policies and coverage in Europe. Euro Surveill 2012; 17:pii:20064.
128. Verstraeten T, Cohet C, Dos Santos G, et al. Pandemrix and narcolepsy: a critical appraisal of the observational studies. Hum Vaccin Immunother 2016; 12:187-193.
129. Montplaisir J, Petit D, Quinn MJ, et al. Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec. PLoS One 2014; 9:e108489.
130. Morel S, Didierlaurent A, Bourguignon P, et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29:2461-2473.
131. Barker CI, Snape MD. Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. Lancet Infect Dis 2014; 14:227-238.
132. Melen K, Partinen M, Tynell J, et al. No serological evidence of influenza A H1N1pdm09 virus infection as a contributing factor in childhood narcolepsy after Pandemrix vaccination campaign in Finland. PLoS One 2013; 8:e68402.
133. Ahmed SS, Volkmuth W, Duca J, et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med 2015; 7:294ra105.
134. Mignot E, Hayduk R, Black J, et al. HLA DQB1∗0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997; 20:1012-1020.
135. Tafti M, Hor H, Dauvilliers Y, et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep 2014; 37:19-25.
136. van der Heide A, Hegeman-Kleinn IM, Peeters E, et al. Immunohistochemical screening for antibodies in recent onset type 1 narcolepsy and after H1N1 vaccination. J Neuroimmunol 2015; 283:58-62.
137. Liblau RS, Vassalli A, Seifinejad A, et al. Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol 2015; 14:318-328.
138. Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the2009 H1N1 pandemicinChina.Ann Neurol 2011;70:410-417.
139. Toyoda H, Miyagawa T, Koike A, et al. A polymorphism in CCR1/CCR3 is associated with narcolepsy. Brain Behav Immun 2015; 49:148-155.
140. Han F, Lin L, Li J, et al. TCRA, P2RY11, and CPT1B/CHKB associations in Chinese narcolepsy. Sleep Med 2012; 13:269-272.
141. Kornum BR, Kawashima M, Faraco J, et al. Common variants in P2RY11 are associated with narcolepsy. Nat Genet 2011; 43:66-71.
142. Han F, Faraco J, Dong XS, et al. Genome wide analysis of narcolepsy in China implicates novel immune loci and reveals changes in association prior to versus after the 2009 H1N1 influenza pandemic. PLoS Genet 2013; 9:e1003880.
143. Hallmayer J, Faraco J, Lin L, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009; 41:708-711.
144. Ollila HM, Ravel JM, Han F, et al. HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy. Am J Hum Genet 2015; 96:136-146.
145. Tafti M, Lammers GJ, Dauvilliers Y, et al. Narcolepsy-associated HLA class I alleles implicate cell-mediated cytotoxicity. Sleep 2016; 39:581-587.
146. Hohjoh H, Terada N, Kawashima M, et al. Significant association of the tumor necrosis factor receptor 2 (TNFR2) gene with human narcolepsy. Tissue Antigens 2000; 56:446-448.
147. Bomfim IL, Fink K, Lamb F, et al. Genetic study of Pandemrix-associated narcolepsy. J Neuroimmunol 2014; 275:50-51.
148. Juji T, Satake M, Honda Y, et al. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 1984; 24:316-319.
149. Seignalet J, Billiard M. Possible association between HLA-B7 and narcolepsy. Tissue Antigens 1984; 23:188-189.
150. Langdon N, Welsh KI, van Dam M, et al. Genetic markers in narcolepsy. Lancet 1984; 2:1178-1180.
151. Black JL 3rd, Silber MH, Krahn LE, et al. Analysis of hypocretin (orexin) antibodies in patients with narcolepsy. Sleep 2005; 28:427-431.
152. Overeem S, Verschuuren JJ, Fronczek R, et al. Immunohistochemical screening for autoantibodies against lateral hypothalamic neurons in human narcolepsy. J Neuroimmunol 2006; 174:187-191.
153. Deloumeau A, Bayard S, Coquerel Q, et al. Increased immune complexes of hypocretin autoantibodies in narcolepsy. PLoS One 2010; 5:e13320.
154. Tanaka S, Honda Y, Inoue Y, et al. Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy. Sleep 2006; 29:633-638.
155. Thebault S, Waters P, Snape MD, et al. Neuronal antibodies in children with or without narcolepsy following H1N1-AS03 vaccination. PLoS One 2015; 10:e0129555.
156. Cvetkovic-Lopes V, Bayer L, Dorsaz S, et al. Elevated tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest 2010; 120:713-719.
157. Kawashima M, Lin L, Tanaka S, et al. Anti-tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep 2010; 33:869-874.
158. Toyoda H, Tanaka S, Miyagawa T, et al. Anti-tribbles homolog 2 autoanti-bodies in Japanese patients with narcolepsy. Sleep 2010; 33:875-878.
159. Lind A, Ramelius A, Olsson T, et al. A/H1N1 antibodies and TRIB2 auto-antibodies in narcolepsy patients diagnosed in conjunction with the Pan-demrix vaccination campaign in Sweden 2009-2010. J Autoimmun 2014; 50:99-106.
160. Saariaho AH, Vuorela A, Freitag TL, et al. Autoantibodies against ganglioside GM3 are associated with narcolepsy-cataplexy developing after Pandemrix vaccination against 2009 pandemic H1N1 type influenza virus. J Autoimmun 2015; 63:68-75.
161. Lecendreux M, Libri V, Jaussent I, et al. Impact of cytokine in type 1 narcolepsy: role of pandemic H1N1 vaccination? J Autoimmun 2015; 60:20-31.
162. Kornum BR, Pizza F, Knudsen S, et al. Cerebrospinal fluid cytokine levels in type 1 narcolepsy patients very close to onset. Brain Behav Immun 2015; 49:54-58.
163. Dauvilliers Y, Carlander B, Rivier F, et al. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004; 56:905-908.
164. Donjacour CE, Lammers GJ. A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy. J Sleep Res 2012; 21:479-480.
165. Tabuchi S, Tsunematsu T, Black SW, et al. Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function. J Neurosci 2014; 34:6495-6509.